167 related articles for article (PubMed ID: 31794091)
1. The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.
Pardy L; Rosati R; Soave C; Huang Y; Kim S; Ratnam M
Prostate; 2020 Feb; 80(2):198-208. PubMed ID: 31794091
[TBL] [Abstract][Full Text] [Related]
2. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.
Patki M; Chari V; Sivakumaran S; Gonit M; Trumbly R; Ratnam M
J Biol Chem; 2013 Apr; 288(16):11047-65. PubMed ID: 23426362
[TBL] [Abstract][Full Text] [Related]
3. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth.
Rosati R; Patki M; Chari V; Dakshnamurthy S; McFall T; Saxton J; Kidder BL; Shaw PE; Ratnam M
J Biol Chem; 2016 Dec; 291(50):25983-25998. PubMed ID: 27793987
[TBL] [Abstract][Full Text] [Related]
4. Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Kawahara T; Aljarah AK; Shareef HK; Inoue S; Ide H; Patterson JD; Kashiwagi E; Han B; Li Y; Zheng Y; Miyamoto H
Prostate; 2016 Jun; 76(8):744-56. PubMed ID: 26864615
[TBL] [Abstract][Full Text] [Related]
5. The expression of ELK transcription factors in adult DRG: Novel isoforms, antisense transcripts and upregulation by nerve damage.
Kerr N; Pintzas A; Holmes F; Hobson SA; Pope R; Wallace M; Wasylyk C; Wasylyk B; Wynick D
Mol Cell Neurosci; 2010 Jun; 44(2):165-77. PubMed ID: 20304071
[TBL] [Abstract][Full Text] [Related]
6. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
7. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
8. Locations of the ets subfamily members net, elk1, and sap1 (ELK3, ELK1, and ELK4) on three homologous regions of the mouse and human genomes.
Giovane A; Sobieszczuk P; Mignon C; Mattei MG; Wasylyk B
Genomics; 1995 Oct; 29(3):769-72. PubMed ID: 8575773
[TBL] [Abstract][Full Text] [Related]
9. Identification of ELK1 interacting peptide segments in the androgen receptor.
Soave C; Ducker C; Kim S; Strahl T; Rosati R; Huang Y; Shaw PE; Ratnam M
Biochem J; 2022 Jul; 479(14):1519-1531. PubMed ID: 35781489
[TBL] [Abstract][Full Text] [Related]
10. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
11. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
12. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A
Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223
[TBL] [Abstract][Full Text] [Related]
13. The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-Terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain.
Soave C; Ducker C; Islam N; Kim S; Yurgelevic S; Nicely NI; Pardy L; Huang Y; Shaw PE; Auner G; Dickson A; Ratnam M
Mol Pharmacol; 2023 Apr; 103(4):211-220. PubMed ID: 36720643
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation can regulate the activity of ETS-like transcription factor 4.
Kaikkonen S; Makkonen H; Rytinki M; Palvimo JJ
Biochim Biophys Acta; 2010 Aug; 1799(8):555-60. PubMed ID: 20637912
[TBL] [Abstract][Full Text] [Related]
15. Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells.
Makkonen H; Jääskeläinen T; Pitkänen-Arsiola T; Rytinki M; Waltering KK; Mättö M; Visakorpi T; Palvimo JJ
Oncogene; 2008 Aug; 27(36):4865-76. PubMed ID: 18469865
[TBL] [Abstract][Full Text] [Related]
16. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway.
Xie W; Li S; Guo H; Zhang J; Tu M; Wang R; Lin B; Wu Y; Wang X
Cancer Med; 2023 Jul; 12(14):15317-15336. PubMed ID: 37326412
[TBL] [Abstract][Full Text] [Related]
18. ERK Signaling Controls Innate-like CD8
Maurice D; Costello P; Sargent M; Treisman R
J Immunol; 2018 Sep; 201(6):1681-1691. PubMed ID: 30068599
[TBL] [Abstract][Full Text] [Related]
19. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
